PFA Pension Forsikringsaktieselskab Purchases Shares of 37,992 Insulet Corporation $PODD

PFA Pension Forsikringsaktieselskab acquired a new stake in Insulet Corporation (NASDAQ:PODD) during the fourth quarter, Holdings Channel.com reports. The firm acquired 37,992 shares of the medical instruments supplier’s stock, valued at approximately $10,905,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PODD. NewEdge Advisors LLC lifted its stake in shares of Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 64 shares during the period. Cresset Asset Management LLC lifted its stake in shares of Insulet by 7.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares during the period. Cerity Partners LLC lifted its stake in shares of Insulet by 68.7% in the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 7,030 shares during the period. Sei Investments Co. lifted its stake in shares of Insulet by 27.4% in the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after purchasing an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina lifted its stake in shares of Insulet by 2.5% in the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after purchasing an additional 791 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Leerink Partners dropped their price objective on Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Truist Financial dropped their price objective on Insulet from $360.00 to $315.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. Evercore dropped their price target on Insulet from $340.00 to $240.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. BTIG Research dropped their price target on Insulet from $380.00 to $320.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Finally, JPMorgan Chase & Co. dropped their price target on Insulet from $415.00 to $340.00 and set an “overweight” rating on the stock in a research note on Thursday, February 19th. Eighteen equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $327.24.

Insulet Stock Performance

PODD stock opened at $175.04 on Monday. The firm has a market cap of $12.12 billion, a PE ratio of 50.01, a P/E/G ratio of 1.03 and a beta of 1.20. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The business has a 50 day moving average of $216.37 and a 200-day moving average of $267.14. Insulet Corporation has a 12-month low of $158.35 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to analyst estimates of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.Insulet’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.15 earnings per share. As a group, sell-side analysts expect that Insulet Corporation will post 6.27 earnings per share for the current year.

Insider Activity

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The stock was bought at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.